Nom du produit:6-Bromo-3,4-dichloroquinoline
IUPAC Name:6-bromo-3,4-dichloroquinoline
- CAS：927801-17-0
- Formule moléculaire：C9H4BrCl2N
- Pureté：97%
- Numéro de catalogue：CM260590
- Poids moléculaire：276.94
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:927801-17-0
- Formule moléculaire:C9H4BrCl2N
- Point de fusion:-
- Code SMILES:ClC1=C(Cl)C=NC2=CC=C(Br)C=C12
- Densité:
- Numéro de catalogue:CM260590
- Poids moléculaire:276.94
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Quinolines
- Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
- Quinoline Price
- if you have any question on quinoline price, we will give the professional answers to your short questions.
Column Infos
- Paltusotine
- Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease.
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome.
Recherche 
+86 21 5895 0110 
